Compare Nokia Corp (NOK) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Pfizer Inc — how do they compare? Nokia Corp trades at $10.74 (market cap $59.77B), while Pfizer Inc trades at $27.89 (market cap $158.39B). The key difference: Pfizer Inc is far larger — about 2.6× Nokia Corp's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| NOK | PFE | |
|---|---|---|
Market Cap | $59.77B | $158.39B |
Sector | Technology | Health |
52-Week High | $16.83 | $29.02 |
52-Week Low | $4.51 | $23.60 |
Enterprise Value | $57.71B | $209.89B |
Dividend Yield | 1.53% | 6.19% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% on the day, supported by a bullish technical signal and positive momentum from AI-driven network infrastructure growth. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with revenue stabilizing around $20 billion annually. Analyst sentiment is predominantly bullish, with 61.5% recommending Buy, amid news of its return to the Euro Stoxx 50 index and expansion in Saudi AI research.
The outlook is cautiously optimistic, driven by AI and cloud demand, but risks include competitive pressures, volatile cash flow, and high valuation multiples. Investment opportunity hinges on execution of growth initiatives, while shareholders face exposure to telecom sector volatility and margin challenges.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
